SEVERE ATOPIC DERMATITIS AND T-CELL LYMPHOMA: SIMILARITIES AND DIFFERENCES



Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

The review is devoted to severe atopic dermatitis and T-cell lymphoma, similarities and differences in their pathogenesis and clinical features.

Full Text

Restricted Access

About the authors

D D Niyasov

Institute of Immunology

Moscow, Russia

E S Fedenko

Institute of Immunology

Moscow, Russia

M N Boldireva

Institute of Immunology

Moscow, Russia

References

  1. Николаева ТВ. Медико-социальные аспекты инвалидности детей с патологией кожи и подкожной клетчатки: Автореф. диссертации канд. мед. наук. М., 2006, 24 с.
  2. Lewis-Jones M.S., Finlay A.Y., Dykes P.J. The Infants Dermatitis Quality of Life Index. Br. J. Dermatol. 2001. v. 144. p. 104-110.
  3. Arellano F.M., Wentwortth C.E., Arana A., Fernandez C. Risk of Lymphoma following exposure to calcineurin inhibitors and topical steroids in patients with atopic dermatitis. J. Invest Dermatol. 2007, v. 127, p. 808-816.
  4. Феденко Е.С. Системный подход в лечении атопического дерматита. Леч. врач. 2003, № 3, с. 36-22.
  5. Cooper K.D. Atopic Dermatitis: recent trends in pathogenesis and therapy. J. Invest Dermatol. 2003, v. 102, p. 128-137.
  6. Bieber T., Novak N. New concepts of atopic dermatitis. From non IgE-mediated to autoimmune inflammation. Alergy Clin. Immunology. 2005, v. 17, p. 26-29.
  7. Novak N., Valenta R., Bohle B. et al. Fcepsilon RI engagement of Langerhans cell-like dendritic cells and inflammatory dendritic epidermal cell-like dendritic cells induces chemotactic signals and different T-cell phenotypes in vitro. J. Allergy Clin. Immunol. 2004, v. 113, p. 949-957.
  8. Howell M.D., Novak N., Bieber T, Pastore S., Girolomoni G., Boguniewicz M., Streib J., Wong C., Gallo R.L., Leung D.Y., Interleukin-10 downregulates anti-microbial peptide expression in atopic dermatitis. J. Invest Dermatol. 2005, v. 125 (4), p. 738-745.
  9. Гребенченко Е.И. Изучение холинергической составляющей кожного зуда при атопическом дерматите и возможность ее фармакологического контроля. Диссертация канд. мед. наук. 2009, 158 с.
  10. Dhar S., Malakar R., Chattopadhyay S. Correlation of the severity of atopic dermatitis with absolute eosinophil counts in peripheral blood and serum IgE levels. Indian J. Dermatol Venerol. Leprol. 2005, v. 71, p. 246-249.
  11. Maintz L., Novak N. Getting and more complex: the pathophysiology of atopic eczema. Eur. J. Dermatol. 2007, v. 17, p. 267-283.
  12. Cooper K.D. Atopic Dermatitis: recent trends in pathogenesis and therapy. J. Invest Dermatol. 2003, v. 102, p. 128-137.
  13. Bos J.D., Brenninkmeijer E.E., Schram M.E. et al. Atopic eczema or atopiform dermatitis. Exp. Dermatol. 2010, v. 19, p. 325-331.
  14. Pace L. IL-4 modulation of CD4+CD25+T regulatory cells mediated suppression. J. Immunol. 2006, v. 174, p. 7645-7653.
  15. Leung D.Y., Bieber T Atopic dermatitis. Lancet. 2003, v. 361, p. 151-160.
  16. Пампура А.Н. Клинико-иммунологическая характеристика различных форм атопического дерматита у детей и оптимизация его лечения. Автореф. диссертации д-ра мед. наук. М., 2003, 49 с.
  17. Клиническая аллергология. Под ред. Р. М. Хаитова. М.; «МЕДпресс-форм». 2002, 623 с.
  18. Ellis C., Luger T., Abeck D. et al. Аллергология, 2003, No. 4. c. 50.
  19. Arellano F.M., Arana A., Wentworth C.E., Fernandez-Vid-aurre C., Schlienger R.G., Conde E. Lymphoma among patients with atopic dermatitis and/or treated with topical immunosuppressants in the United Kingdom. J. Allergy Clin. Immunol. 2009, v. 123, p. 1111-1116.
  20. Тарасенко Ю.Г. Клиническая и морфоиммуногистохимическая дифференциальная диагностика лимфом кожи. Автореф. диссертации канд. мед. наук. 2008, с 11.
  21. Sokolowska M.W., Baranska W., Cegielska A. Atopic dermatitis-like Pre-Sezary syndrome: Role of Immunosupression, Actaderm. Venereol. 2011, v. 91, p. 574-577.
  22. Willimze R., Meijer C.J. Rationale of a new classification for the group of primary cutaneous lymphomas. Semin. Cutan. Med. Surg. 2000, v. 19, p. 71-77.
  23. Hoppe R.T. Hodgkin’s disease/Textbook of Radiation Oncology Ed. by Leibl S.A. and Phillips T.L., W.B. Saunders Company, Philadelphia. 1999, 1079 p.
  24. Armitage J.O., His E.D., Foss F.M. Clinical roundtable monograph. T-cell lymphoma: therapeutic overview and disease state awareness. Clin. Adv. Hematol. Oncol. 2010, v. 8, p. 1-15.
  25. Wong H.K., Mishra A., Hake T., Porcu P. Evolving insights in the pathogenesis and therapy of cutaneous T-cell lymphoma (mycosis fungoides and Sezary syndrome). Br. J. Haematol. 2011, v. 155 (2), p. 150-166.
  26. Leroy S., Dubois S., Tenaud I., Chebassier N., Godard A., Jacques Y., Dréno B. Interleukin-15 expression in cutaneous T-cell lymphoma (mycosis fungoides and Sézary syndrome). Br. J. Dermatol. 2001, v. 144 (5), p. 1016-1023.
  27. Dalloul A., Laroche L., Bagot M. Interleukin-7 is a growth factor for Sezry lymphoma cells. J. Clin. Invest. 1992, v. 90, p. 105.
  28. Merle-Beral H., Scmitt C., Mossalayi D. Interleukin-7 and malignant T-cells Nouv. Rev. Fr. Hematol. 1993, v. 35, p. 231-232.
  29. Rook A.H., Kubin M. Cassin M. IL-12 reverses cytokine and immune abnormalities in Sezary syndrome. J. Immunol. 2005, v. 154, p. 1491-1498.
  30. Borish L.,Dishuck J., Cox L. et al. Sezary syndrome with elevated serum IgE and hypereosinophila-role of dysregulated cytokine production. J. Allerg. Clin. Immunol. 2003, v. 92, p. 123-131.
  31. Лезвинская Е.М., Овсянникова Г.В. Особенности диагностики различных нозологических форм злокачественных лимфом кожи. Дерматовенерология. 2009, № 1, с. 110.
  32. Ашмарин Ю.Я. Поражения кожи и слизистых оболочек при ретикулезах. Медицина. 1992, № 3, с. 187.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright © Pharmarus Print Media, 2012



This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies